Thermo Fisher Scientific Inc. announced an expansion of its partnership with Sanofi to enable additional U.S. drug product manufacturing by acquiring Sanofi’s steriles manufacturing site in Ridgefield.
The Massachusetts-based life science and clinical research company said it will continue to manufacture a portfolio of therapies for Sanofi and plans to expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.
The Ridgefield site is a state-of-the-art sterile fill-finish and packaging facility with a world-class team of more than 200 employees who will join Thermo Fisher following the completion of the transaction.
The terms of the deal were not disclosed.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” Marc Casper, chairman, president and chief executive officer of Thermo Fisher said. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
Brendan O’Callaghan, global head of manufacturing & supply, Sanofi, added, “This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site.”
Thermo Fisher operates a leading global sterile fill-finish manufacturing network, which currently includes U.S. sites in Greenville, North Carolina and Plainville, Massachusetts.
The transaction is expected to be completed in the second half of 2025, subject to customary closing conditions. Upon completion of the transaction, Sanofi’s Ridgefield facility will become part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment.
